Navigation Links
MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Date:3/1/2011

Announced results from a clinical trial comparing the pharmacokinetics and safety of LEVADEX and intravenous dihydroergotamine (DHE) in smokers and non-smokers. The trial was designed to measure whether systemic absorption and exposure in smokers is greater than in non-smokers. In the trial, the systemic absorption of LEVADEX was not higher and systemic exposure to DHE was not greater in smokers than in non-smokers.
  • Announced results from a pharmacodynamics trial evaluating pulmonary artery pressure in healthy volunteers using echocardiogram. The trial compared acute effects on pulmonary artery pressure of LEVADEX, DHE administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.
  • Announced results from a thorough QT trial in healthy adults comparing the acute effects of a supra-therapeutic dose of LEVADEX, oral moxifloxacin and placebo on the cardiac QT interval as measured by electrocardiogram. Results of the trial showed that a supra-therapeutic dose of LEVADEX does not increase QTc intervals.  
  • Announced completion of the LEVADEX open-label safety trial. In total, more than 475 patients completed six months treatment and more than 250 patients completed 12 months treatment.  No drug-related serious adverse events were reported.
  • Presented additional analyses of the LEVADEX Phase 3 FREEDOM-301 trial at various medical meetings, including data for LEVADEX in a broad spectrum of acute migraine attacks; menstrual migraine; allodynic patients; resistant migraine; patients with concomitant asthma; migraine recurrence; and the administration of LEVADEX at different time points during migraine attacks.

  • Corporate

  • Announced a collaboration with Allergan to co-promote LEVADEX to neurologists and pain specialists in the United States for th
    '/>"/>

  • SOURCE MAP Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
    2. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
    3. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
    4. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
    5. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
    6. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
    7. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
    8. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
    9. Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)
    10. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
    11. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/31/2015)...  US-Australian drug discovery company, Novogen Limited (ASX: ... comprehensive scientific review has identified high value opportunities ... unmet patient need. Novogen is moving as quickly ... to entering into Phase 1 clinical trials with ... Executive Officer, Iain Ross , said that ...
    (Date:8/31/2015)... Aug. 31, 2015 LabStyle Innovations Corp. ... Solution, today announced it recently closed a round ... be used to support the global rollout and ... mobile, cloud-based, diabetes management solution that includes novel ... blood glucose monitoring device, and for working capital ...
    (Date:8/31/2015)... ... 31, 2015 , ... The Food Processing Suppliers Association's PROCESS ... equipment manufacturers and leaders in the field of academia. , METTLER TOLEDO ... manufacturers of bakery and snacks; beverages; dairy; meat, poultry and seafood; and prepared ...
    (Date:8/30/2015)... CHERTSEY , England , August ... Kampagne beendet die 51-jährige Wartezeit   einer Frau   ... und Frauen im Alter von 7-90   ... Programm soll 1200 Frauen behandeln und ...     , Astellas gab heute ...
    Breaking Biology Technology:Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 2LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 3LabStyle Innovations Closes $2.5 Million Funding to Support Global Rollout of Dario Diabetes Management Solution 4METTLER TOLEDO Hosts Food Safety Educational Center at 2015 PROCESS EXPO 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5
    ... , , ... Corporation (Pink Sheets: CGCP), a market leader in laser transmyocardial ... (Investigational Device Exemption) to the Food and Drug Administration to ... with refractory angina. The PHOENIX Combination Delivery System combines ...
    ... TAINAN, Taiwan, July 30 /PRNewswire-Asia/ -- Eli Lilly ... today that they have,reached an amicable resolution of ... ScinoPharm,s manufacture and sale of gemcitabine,hydrochloride around the ... of the settlement, Lilly has granted ScinoPharm a ...
    ... LAUSANNE, Switzerland and MEDFORD, Massachussets, July 30 ... companies with a focus on the development of ... Protein Technologies (MSM), a human,antibody drug discovery company ... announce the signature of an exclusive,agreement for the ...
    Cached Biology Technology:Cardiogenesis Corporation Makes Pre-IDE Submission for PHOENIX Combination Delivery System 2Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation 2Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 2Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 3Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 4
    (Date:8/31/2015)... Growing need for data security ... projects to drive India biometrics market ... report, " India Biometrics Market Forecast & Opportunities, 2020 ", ... to grow at a CAGR of over 35% during 2015 ... of extensive use of biometric technology in the government sector. ...
    (Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/st5b3m/saudi_arabia ) has announced ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Biomedical Sensors market is estimated at $0.23 billion by ... 2014-2020 The near future will bring biomedical ... each individual. These sensors can be set to trigger ...
    (Date:8/28/2015)... August 28, 2015 According to ... Market by Assessment Type (Pen & Paper Based, Hosted, ... Corporate Learning, Academic Research), Vertical and Region - Global ... Training Market to grow from USD 2.4 Billion in ... Compound Annual Growth Rate (CAGR) of 25.6% from 2015 ...
    Breaking Biology News(10 mins):India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 2India Biometrics Market to Grow at Over 35% Through 2020, Says TechSci Research 3Saudi Arabia Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts (2014-2020) 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4
    ... at the Smithsonian,s National Zoo detected a secondary rise ... panda Mei Xiang (may-SHONG) earlier this month. The results ... to believe the hormone rise indicates that it would ... birth to a cub or comes to the end ...
    ... 20, 2008) The future of high-intensity x-ray science ... Department of Energy,s Argonne National Laboratory have devised a ... free electron laser oscillator (X-FELO) we are proposing can ... than currently operating machines," Argonne Distinguished fellow Kwang-Je Kim ...
    ... as temperatures warm along the East Coast of the ... less likely they are to keep pace with the ... the Manomet Center for Conservation Sciences analyzed changes in ... birds along the coast of eastern Massachusetts since 1970. ...
    Cached Biology News:A novel X-ray source could be brightest in the world 2Birds migrate earlier, but some may be left behind as the climate warms rapidly 2